Physician profile
Timothy Pearson
NPI 1972845121
$3,074.24
in general payments reported to CMS, 2019-2025
27 companies · $848 in 2025
The $848 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $45.71 · 2021: $124 · 2022: $328 · 2023: $706 · 2024: $670 · 2025: $848.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,216 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,216.32 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $480.57 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $398.90 | 2021-2025 | Ilumya |
| Pfizer INC. | $287.07 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $274.12 | 2023-2025 | |
| Leo Pharma INC. | $212.16 | 2019-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $210.10 | 2019-2024 | Tremfya, Simponi Aria, Stelara |
| E.R. Squibb & Sons, L.L.C. | $205.68 | 2023-2025 | Sotyktu |
| Epi Health, LLC | $180.30 | 2019 | |
| Arcutis Biotherapeutics, INC. | $172.30 | 2023-2025 | Zoryve |
| Regeneron Healthcare Solutions, INC. | $150.83 | 2019-2025 | Dupixent |
| Galderma Laboratories, L.P. | $104.71 | 2024-2025 | Nemluvio |
| Ucb, INC. | $84.34 | 2023-2025 | Bimzelx, Cimzia |
| Amgen INC. | $81.79 | 2020-2025 | Otezla |
| Almirall LLC | $24.60 | 2023 | Klisyri |
| Kerecis Limited | $20.15 | 2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $19.89 | 2019 | |
| Lilly USA, LLC | $18.16 | 2023 | Taltz, Olumiant |
| Dusa Pharmaceuticals, INC. | $17.76 | 2019 | |
| Biofrontera INC. | $17.75 | 2025 | |
| Dermavant Sciences, INC. | $17.66 | 2023 | Vtama |
| Hill Dermaceuticals, INC. | $15.14 | 2022 | |
| Botanix Sb INC | $15.02 | 2025 | Sofdra |
| Janssen Scientific Affairs, LLC | $14.87 | 2021 | |
| Mission Pharmacal Company | $14.02 | 2019 | |
| Strata Skin Sciences, INC. | $13.67 | 2021 | |
| Merck Sharp & Dohme LLC | $13.27 | 2019 | |
| Organon LLC | $9.41 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Pearson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.